Medication Monitor

Generic Name (Trade Name—Company)
May 20, 2011


(Edurant—Tibotec Therapeutics)
NNRTI for management of HIV-1 infection


Treatment of HIV-1 in treatment-naive adults 

Rilpivirine is the newest nonnucleoside reverse transcriptase inhibitor (NNRTI) for use in combination with other antiretroviral agents in treatment-naive adults. The recommended dose is one 25-mg tablet once daily with a meal. Approval was based on 48-week data from two Phase III trials and 96-week data from a Phase IIb trial that showed efficacy comparable to regimens that added efavirenz (Sustiva—Bristol-Myers Squibb). The most common adverse events of at least moderate to severe intensity were depression, insomnia, headache, and rash.